CoChat

Antihypertensive and Lipid-Lowering Medication Adherence in Young Adults With Youth-Onset Type 2 Diabetes

Weinstock, Ruth S., Trief, Paula M., Burke, Brian K., Wen, Hui, Liu, Xun, Kalichman, Seth, Anderson, Barbara J., Bulger, Jane D. · 2023 · JAMA Network Open
Cited by 23

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Importance: Youth-onset type 2 diabetes is associated with early development of chronic complications. Treatment of elevated blood pressure (BP), nephropathy, and dyslipidemia are critical to reduce morbidity. Data are needed on adherence to BP- and lipid-lowering medications in young adults with youth-onset diabetes. Objective: To assess adherence and factors associated with adherence to BP- and lipid-lowering medications in young adults with youth-onset type 2 diabetes and diagnoses of hypertension, nephropathy, or dyslipidemia. Design, Setting, and Participants: This cohort study measured medication adherence with 3 monthly unannounced pill counts at 2 time points 1 year apart during iCount, conducted during the last years (2017-2019) of the observational phase of the Treatment Options for Type 2 Diabetes in Adolescents and Youth study. Psychosocial factors associated with medication adherence were examined. Participants included individuals with youth-onset type 2 diabetes with hypertension, nephropathy, or dyslipidemia receiving diabetes care in their communities. Data were analyzed from September 2022 to September 2023. Main Outcomes and Measures: The main outcome was BP- and lipid-lowering medication adherence, with low adherence defined as using less than 80% of pills and high adherence, at least 80% of pills. Psychosocial factors were measured using the Beliefs about Medicines Questionnaire and Material Needs Insecurities Survey. Results: Of 381 participants in iCount, 243 participants (mean [SD] age, 26.12 [2.51] years; 159 [65.43%] women) with hypertension, nephropathy, or dyslipidemia were included in analysis. Among 196 participants with hypertension or nephropathy, 157 (80.1%) had low adherence. Participants with low adherence, compared with those with high adherence, were younger (mean [SD] age, 25.99 [2.41] vs 27.26 [2.41] years; P = .005), had higher glycated hemoglobin A 1c (mean [SD], 10.33% [2.66 percentage points] vs 8.85% [2.39 percentage points]; P = .001), shorter diabetes duration (mean [SD], 12.32 [1.49] vs 12.90 [1.46] years; P = .03), and less education (eg, 17 participants [10.83%] vs 0 participants with no high school diploma; P = .004). Of 146 participants with dyslipidemia, 137 (93.8%) had low adherence and only 9 participants (6.2%) had high adherence. Of 103 participants with low adherence to BP-lowering medications and using oral hypoglycemic agents, 83 (80.58%) had low adherence to oral hypoglycemic agents. Beliefs that medications are necessary were higher for participants with high adherence to BP-lowering medications than those with low adherence in unadjusted analyses (mean [SD] necessity score, 16.87 [6.78] vs 13.89 [9.15]; P = .03). In adjusted multivariable analyses of participants with hypertension or nephropathy, having at least 1 unmet social need (odds ratio [OR], 0.20; 95% CI, 0.05-0.65; P = .04) and medication concerns (OR, 0.63; 95% CI, 0.40-0.96; P = .01) were associated with worse medication adherence 1 year follow-up. Diabetes distress, self-efficacy, depressive and anxiety symptoms, and self-management support were not associated with 1-year medication adherence. Conclusions and Relevance: These findings suggest that adherence to BP- and lipid-lowering medications was very poor in this cohort. To improve medication adherence and prevent early vascular events, approaches that identify and address medication concerns and unmet social needs are needed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamanetworkopen.2023.36964

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 44

  1. Al-Saeed, 2016, An inverse relationship between age of type 2 diabetes onset and complication risk and mortality: the impact of youth-onset type 2 diabetes., Diabetes Care, 39, 823, 10.2337/dc15-0991 · DOI · Paper page
  2. Dabelea, 2014, Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009., JAMA, 311, 1778, 10.1001/jama.2014.3201 · DOI · Paper page
  3. Mayer-Davis, 2017, Incidence trends of type 1 and type 2 diabetes among youths, 2002–2012., N Engl J Med, 376, 1419, 10.1056/NEJMoa1610187 · DOI · Paper page
  4. Dabelea, 2017, Association of type 1 diabetes vs type 2 diabetes diagnosed during childhood and adolescence with complications during teenage years and young adulthood., JAMA, 317, 825, 10.1001/jama.2017.0686 · DOI · Paper page
  5. Lynch, 2020, Country-specific prevalence and incidence of youth-onset type 2 diabetes: a narrative literature review., Ann Nutr Metab, 76, 289, 10.1159/000510499 · DOI
  6. Mallik, 2022, Pharmacotherapy to delay the progression of diabetic kidney disease in people with type 2 diabetes: past, present and future., Ther Adv Endocrinol Metab, 10.1177/20420188221081601 · DOI
  7. Bjornstad, 2023, Youth-onset type 2 diabetes mellitus: an urgent challenge., Nat Rev Nephrol, 19, 168, 10.1038/s41581-022-00645-1 · DOI
  8. Lee, 2021, Adherence to antihypertensive medication and incident cardiovascular events in young adults with hypertension., Hypertension, 77, 1341, 10.1161/HYPERTENSIONAHA.120.16784 · DOI
  9. Gatwood, 2021, Alignment of diagnosis and pharmacy claims data coding of medication adherence among patients with diabetes or hypertension., J Manag Care Spec Pharm, 27, 497, 10.18553/jmcp.2021.27.4.497 · DOI
  10. Taha, 2022, Cost-related medication nonadherence in adults with diabetes in the United States: the National Health Interview Survey 2013-2018., Diabetes Care, 45, 594, 10.2337/dc21-1757 · DOI
  11. Rodriguez, 2019, Association of statin adherence with mortality in patients with atherosclerotic cardiovascular disease., JAMA Cardiol, 4, 206, 10.1001/jamacardio.2018.4936 · DOI · Paper page
  12. Chehal, 2023, Continuity of medication use by US adults with diabetes, 2005-2019., JAMA Netw Open, 6, 10.1001/jamanetworkopen.2022.53562 · DOI
  13. Zeitler, 2012, A clinical trial to maintain glycemic control in youth with type 2 diabetes., N Engl J Med, 366, 2247, 10.1056/NEJMoa1109333 · DOI · Paper page
  14. Trief, 2022, Medication adherence in young adults with youth-onset type 2 diabetes: iCount, an observational study., Diabetes Res Clin Pract, 184, 10.1016/j.diabres.2022.109216 · DOI · Paper page
  15. Trief, 2022, Association of psychosocial factors with medication adherence in emerging adults with youth-onset type 2 diabetes: the iCount study., Pediatr Diabetes, 23, 1695, 10.1111/pedi.v23.8 · doi:10.1111/pedi.v23.8
  16. Raymond, 2017, Use of unannounced telephone pill counts to measure medication adherence among adolescents and young adults living with perinatal HIV infection., J Pediatr Psychol, 42, 1006, 10.1093/jpepsy/jsx064 · DOI
  17. Kalichman, 2008, Monitoring medication adherence by unannounced pill counts conducted by telephone: reliability and criterion-related validity., HIV Clin Trials, 9, 298, 10.1310/hct0905-298 · DOI
  18. Kalichman, 2007, Adherence to antiretroviral therapy assessed by unannounced pill counts conducted by telephone., J Gen Intern Med, 22, 1003, 10.1007/s11606-007-0171-y · DOI
  19. Kalichman, 2010, Monthly unannounced pill counts for monitoring HIV treatment adherence: tests for self-monitoring and reactivity effects., HIV Clin Trials, 11, 325, 10.1310/hct1106-325 · DOI
  20. Fredericksen, 2014, Unannounced telephone-based pill counts: a valid and feasible method for monitoring adherence., AIDS Behav, 18, 2265, 10.1007/s10461-014-0916-7 · DOI
  21. Anderson, 1998, The third version of the Diabetes Attitude Scale., Diabetes Care, 21, 1403, 10.2337/diacare.21.9.1403 · DOI · Paper page
  22. Horne, 1999, The Beliefs About Medicines Questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication., Psychol Health, 14, 1, 10.1080/08870449908407311 · DOI · Paper page
  23. Ritter, 2016, Characteristics of the Spanish- and English-language self-efficacy to manage diabetes scales., Diabetes Educ, 42, 167, 10.1177/0145721716628648 · DOI · Paper page
  24. McGuire, 2010, Short-form measures of diabetes-related emotional distress: the Problem Areas in Diabetes Scale (PAID)-5 and PAID-1., Diabetologia, 53, 66, 10.1007/s00125-009-1559-5 · DOI · Paper page
  25. Kroenke, 2009, The PHQ-8 as a measure of current depression in the general population., J Affect Disord, 114, 163, 10.1016/j.jad.2008.06.026 · DOI · Paper page
  26. Corson, 2004, Screening for depression and suicidality in a VA primary care setting: 2 items are better than 1 item., Am J Manag Care, 10, 839
  27. Spitzer, 2006, A brief measure for assessing generalized anxiety disorder: the GAD-7., Arch Intern Med, 166, 1092, 10.1001/archinte.166.10.1092 · DOI · Paper page
  28. Löwe, 2008, Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population., Med Care, 46, 266, 10.1097/MLR.0b013e318160d093 · DOI · Paper page
  29. Glasgow, 2000, A social-ecologic approach to assessing support for disease self-management: the Chronic Illness Resources Survey., J Behav Med, 23, 559, 10.1023/A:1005507603901 · DOI · Paper page
  30. Glasgow, 2005, The Chronic Illness Resources Survey: cross-validation and sensitivity to intervention., Health Educ Res, 20, 402, 10.1093/her/cyg140 · DOI · Paper page
  31. Berkowitz, 2015, Material need insecurities, control of diabetes mellitus, and use of health care resources: results of the Measuring Economic Insecurity in Diabetes study., JAMA Intern Med, 175, 257, 10.1001/jamainternmed.2014.6888 · DOI · Paper page
  32. Trief, 2023, Psychosocial factors predict medication adherence in young adults with youth-onset type 2 diabetes: longitudinal results from the TODAY2 iCount study., Diabet Med, 40, 10.1111/dme.v40.5 · doi:10.1111/dme.v40.5
  33. Shah, 2022, Cardiovascular risk factor progression in adolescents and young adults with youth-onset type 2 diabetes., J Diabetes Complications, 36, 10.1016/j.jdiacomp.2021.108123 · DOI
  34. Gidding, 2018, Cardiac biomarkers in youth with type 2 diabetes mellitus: results from the TODAY study., J Pediatr, 192, 86, 10.1016/j.jpeds.2017.09.012 · DOI
  35. TODAY Study Group, 2013, Lipid and inflammatory cardiovascular risk worsens over 3 years in youth with type 2 diabetes: the TODAY clinical trial., Diabetes Care, 36, 1758, 10.2337/dc12-2388 · DOI · Paper page
  36. TODAY Study Group, 2020, Longitudinal changes in cardiac structure and function from adolescence to young adulthood in participants with type 2 diabetes mellitus: the TODAY follow-up study., Circ Heart Fail, 13, 10.1161/CIRCHEARTFAILURE.119.006685 · DOI · Paper page
  37. Shah, 2022, Longitudinal changes in vascular stiffness and heart rate variability among young adults with youth-onset type 2 diabetes: results from the follow-up observational treatment options for type 2 diabetes in adolescents and youth (TODAY) study., Acta Diabetol, 59, 197, 10.1007/s00592-021-01796-6 · DOI
  38. Colantonio, 2019, Adherence to statin therapy among US adults between 2007 and 2014., J Am Heart Assoc, 8, 10.1161/JAHA.118.010376 · DOI · Paper page
  39. Hope, 2019, Systematic review of the predictors of statin adherence for the primary prevention of cardiovascular disease., PLoS One, 14, 10.1371/journal.pone.0201196 · DOI · Paper page
  40. Tajeu, 2019, Antihypertensive medication nonpersistence and low adherence for adults <65 years initiating treatment in 2007-2014., Hypertension, 74, 35, 10.1161/HYPERTENSIONAHA.118.12495 · DOI · Paper page
  41. Wilder, 2022, Relationship between social determinants of health and antihypertensive medication adherence in a Medicaid cohort., Circ Cardiovasc Qual Outcomes, 15, 10.1161/CIRCOUTCOMES.121.008150 · DOI
  42. Aikens, 2009, Diabetic patients’ medication underuse, illness outcomes, and beliefs about antihyperglycemic and antihypertensive treatments., Diabetes Care, 32, 19, 10.2337/dc08-1533 · DOI · Paper page
  43. TODAY Study Group, 2022, Longitudinal association of depressive symptoms, binge eating, and quality of life with cardiovascular risk factors in young adults with youth-onset type 2 diabetes: the TODAY2 study., Diabetes Care, 45, 1073, 10.2337/dc21-1995 · DOI
  44. Katz, 2016, Correlates of medication adherence in the TODAY cohort of youth with type 2 diabetes., Diabetes Care, 39, 1956, 10.2337/dc15-2296 · DOI · Paper page

Cited by

See all 23

Metadata

Authors
Weinstock, R. S., Trief, P. M., Burke, B. K., Wen, H., Liu, X., Kalichman, S., Anderson, B. J., & Bulger, J. D.
Affiliations
  • Department of Medicine, State University of New York Upstate Medical University, Syracuse
  • Department of Psychiatry and Behavioral Sciences, State University of New York Upstate Medical University, Syracuse
  • Biostatistics Center, George Washington University, Rockville, Maryland
  • Department of Psychological Sciences, University of Connecticut, Storrs
  • Department of Pediatrics, Baylor College of Medicine, Houston, Texas
Venue
JAMA Network Open
Published
2023-10-04
Volume
6
Issue
10
Pages
e2336964
ISSN
2574-3805
Cited by
23
References
5
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.